Skye Bioscience Inc. will get a new trial on an executive’s claims that she was fired for blowing the whistle on the former CEO’s deceptive public communications about the company’s glaucoma treatment.
A trial judge wrongly admitted evidence of a former Skye board member’s guilty plea and Securities and Exchange Commission judgment, a divided US Court of Appeals for the Ninth Circuit said Tuesday. That evidence had only slight probative value, yet was highly prejudicial to Skye, the 2-1 panel said.
The trial judge permitted the jury to impute the former board member’s misconduct to the company even though it ...
AI-powered legal analytics, workflow tools and premium legal & business news.
Log in to keep reading or access research tools.
WASHINGTON, D.C. — The Trump administration is using a Civil War-era law targeting fraud to go after Google, Verizon and other major corporations for implementing diversity, equity and inclusion (...